Reversal of multidrug resistance with LY335979: Functional analysis of P-glycoprotein-mediated transport activity and its modulation in vivo

Journal of Clinical Pharmacology

Volumn 41, Issue 7 SUPPL., 2001, Pages

  Slapak, Christopher A ^a   Dahlheimer, Julie ^b,c   Piwnica Worms, David ^b,c  

^a ELI LILLY AND COMPANY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; MEMBRANE PROTEIN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; ZOSUQUIDAR; DIAGNOSTIC AGENT; DIBENZO[A,D]CYCLOHEPTENE DERIVATIVE; QUINOLINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

CONFERENCE PAPER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG LABELING; DRUG TRANSPORT; HUMAN; HUMAN CELL; ISOTOPE LABELING; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; PROTEIN TRANSPORT; ACTIVE TRANSPORT; ANIMAL; DRUG EFFECT; GENE; GENETICS; METABOLISM; REVIEW;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; DIBENZOCYCLOHEPTENES; DRUG RESISTANCE, MULTIPLE; GENES, MDR; HUMANS; P-GLYCOPROTEIN; QUINOLINES; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M SESTAMIBI;

EID: 0034743490     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/009127001773744134     Document Type: Conference Paper

References (65)

1. Biochemical, cellular, and pharmacological aspects of the multidrug transporter
2. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
3. Tissue distribution of multidrug resistance protein
4. A multidrug resistance transporter from human MCF-7 breast cancer cells
5. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: Demonstration of homology to ABC transport genes
6. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance
7. Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer drugs
8. Pharmacology of drugs that alter multidrug resistance in cancer
9. PSC 833, a non-immunosuppressive cyclosporin analog, is a very potent multidrug-resistance modifier
10. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative
11. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979
12. Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209, and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP
13. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C
14. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance
15. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1
16. Transfer and expression of the human multiple drug resistance gene into live mice
17. Resistance to taxol chemotherapy produced in mouse marrow cells by safety-modified retroviruses containing a human MDR-1 transcription unit
18. Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy
19. Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells
20. Metal complexes for therapy and diagnosis of drug resistance
21. Functional identification of multidrug resistance gene expression in vivo
22. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex
23. Characterization of multidrug-resistance P-glycoprotein transport function with an organotechnetium cation
24. 99mTc-sestamibi as an agent for imaging P-glycoprotein-mediated multi-drug resistance: In vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant
25. Differences between accumulation of Tc-99m-MIBI and Tl-201-thallous chloride in tumor cells: Role of P-glycoprotein
26. Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: Correlation with mdr gene expression
27. In vivo detection of multidrug resistance (MDR1) phenotype by technetium-99m-sestamibi scan in untreated breast cancer patients
28. Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients
29. Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m-sestamibi
30. Modulation of the multidrug resistance P-glycoprotein: Detection with Tc-99m-sestamibi in vivo
31. Dipyridamole modulated Tc-99m-sestamibi (mibi) scintigraphy: A predictor of response to chemotherapy in patients with small cell lung cancer
32. Clinical validation of the influence of P-glycoprotein on technetium-99m-Sestamibi uptake in malignant tumors
33. Characterization of P-glycoprotein transport and inhibition in vivo
34. Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer
35. Tumor clearance of technetium-99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer
36. Scintigraphic detection of multidrug resistance in cancer
37. Novel hexakis (areneisonitrile) technetium (I) complexes as radioligands targeted to the multidrug resistance P-glycoprotein
38. Characterization of phosphine complexes of technetium (III) as transport substrates of the multidrug resistance (MDR1) P-glycoprotein and functional markers of P-glycoprotein at the blood-brain barrier
39. Technetium-99m-furifosmin as an agent for functional imaging of multidrug resistance in tumors
40. Novel Tc(III)-Q-complexes for functional imaging of the multidrug resistance (MDR1) P-glycoprotein
41. Technetium-99m-tetrofosmin as a substrate for P-glycoprotein: In vitro studies in multidrug-resistant breast tumor cells
42. Effects of MDR1 and MDR3 P-glycoproteins, MRP1 and BCRP/MXR/ABCP on transport of Tc-99m-Tetrofosmin
43. In vitro comparison of sestamibi, tetrofosmin, and furifosmin as agents for functional imaging of multidrug resistance in tumors
44. Visualization of multidrug resistance in vivo
45. Novel gallium (III) complexes transported by MDR1 P-glycoprotein: Potential PET imaging agents for probing P-glycoprotein-mediated transport activity in vivo
46. 11C-colchicine for PET imaging of multiple drug resistance
47. Uptake and retention of hexakis (2-methoxy isobutyl isonitrile) technetium(I) in cultured chick myocardial cells: Mitochondrial and plasma membrane potential dependence
48. Comparison of Tc-99m sestamibi, serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy in small cell lung cancer
49. The toxicity and pharmacokinetic interaction of LY335979, an inhibitor to P-glycoprotein, with doxorubicin in beagle dogs
50. A phase I dose-escalating trial for LY335979, a potent multidrug-resistance modulator, combined with doxorubicin in patients with advance malignancies
51. A phase I and pharmacokinetic study of docetaxel and LY335979 in patients with advanced malignancies
52. A phase I study of vinorelbine plus multidrug resistance (MDR) inhibitor LY 335979 in patients with advanced solid tumors
53. Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance
54. Multidrug resistance and the role of P-glycoprotein knockout mice
55. Choroid plexus epithelial expression of MDR1 P-glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal fluid drug-permeability barrier
56. Modulation of the pharmacokinetics of P-glycoprotein-targeted Tc-99m-complexes by GW0918 (GG918) in wild-type and mdr1a P-glycoprotein knock-out mice
57. P-glycoprotein monitoring of carbon-11 daunorubicin and verapamil in P-glycoprotein gene knock-out and wild type mice with PET
58. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues
59. Membrane potential determination in large unilamellar vesicles with hexakis (2-methoxyisobutyl isonitrile) technetium (I)
60. Uptake of the cation hexakis (2-methoxy isobutylisonitrile) technetium-99m by human carcinoma cell lines in vitro
61. Microprobe analysis of Tc-MIBI in heart cells: Calculation of mitochondrial potential
62. Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of technetium-99m-sestamibi
63. 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein
64. Analysis of ion transport perturbations caused by huMDR1 protein overexpression
65. P-glycoprotein expression by technetium-99m-MIBI scintigraphy in hematologic malignancy